文献速递冠心病

坎格瑞洛联合碾碎替格瑞洛在直接PCI的STEMI患者中的血小板抑制作用

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
PubMed 文献 · Circulation · 2019-01-01

这项前瞻性随机双盲安慰剂对照药效学研究纳入50例行直接PCI的STEMI患者,随机接受坎格瑞洛或安慰剂(团注后2小时输注),所有患者同时服用碾碎的替格瑞洛180mg负荷剂量。结果显示坎格瑞洛在团注后5分钟即显著降低P2Y12反应单位并持续至输注结束,且停药后两组血小板反应性无差异,提示坎格瑞洛可桥接口服替格瑞洛的血小板抑制间隙且无药物相互作用。

要点

  • 坎格瑞洛团注后5分钟即显著降低P2Y12反应单位,效果持续整个输注期。
  • 坎格瑞洛显著降低高治疗血小板反应性发生率。
  • 停药后两组血小板反应性无差异,提示与替格瑞洛无药物相互作用。

核心结论

  • 在直接PCI患者中,坎格瑞洛可有效桥接替格瑞洛口服P2Y12抑制的血小板抑制间隙。
  • 替格瑞洛可碾碎后与坎格瑞洛同时给药,无明显药物相互作用。

研究设计与样本

  • 前瞻性、随机、双盲、安慰剂对照药效学研究,纳入50例行直接PCI的患者。
  • 患者随机接受坎格瑞洛或匹配安慰剂(团注后2小时输注),所有患者同时服用碾碎的替格瑞洛180mg负荷剂量。
  • 在8个时间点进行药效学分析,测量P2Y12反应单位和血小板反应性指数。

主要发现

  • 坎格瑞洛组在团注后5分钟P2Y12反应单位即降低,并持续整个输注期间。
  • 血小板反应性指数显示平行结果,坎格瑞洛组高治疗血小板反应性率降低。
  • 停止坎格瑞洛/安慰剂输注后,两组血小板反应性水平无差异。

关键数值与推荐

  • 替格瑞洛负荷剂量为180mg,碾碎后服用。
  • 坎格瑞洛给药方式为团注后2小时输注。

临床怎么用

  • 对于行直接PCI的STEMI患者,可考虑使用坎格瑞洛桥接替格瑞洛起效前的血小板抑制间隙。
  • 替格瑞洛可碾碎后与坎格瑞洛同时给药,无需担心药物相互作用。

局限性

  • 药效学发现的临床意义尚需在足够样本量的临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (P-PCI). In turn, this leads to a gap in platelet inhibition, exposing patients to an increased risk of early thrombotic complications and underscoring the need to define strategies associated with more effective platelet inhibition in the peri-primary percutaneous coronary intervention period. Cangrelor is an intravenous P2Y12 inhibitor with prompt and potent antiplatelet effects. However, to date, there are limited data on the effects of cangrelor used in combination with ticagrelor in patients undergoing primary percutaneous coronary intervention. Moreover, questions have emerged on the potential for drug-drug interactions during the transition from cangrelor to oral P2Y12 inhibitors. METHODS: This was a prospective, randomized, double-blind, placebo-controlled pharmacodynamic study conducted in patients undergoing primary percutaneous coronary intervention (n=50) who were randomized to treatment with either cangrelor or matching placebo (bolus followed by 2-hour infusion). All patients received ticagrelor 180-mg loading dose administered as crushed tablets at the time of cangrelor/placebo bolus administration. Pharmacodynamic analyses were performed at 8 time points. Pharmacodynamic effects were measured as P2Y12 reaction units by VerifyNow and platelet reactivity index by vasodilator-stimulated phosphoprotein. RESULTS: Compared with placebo, cangrelor was associated with reduced P2Y12 reaction units as early as 5 minutes after bolus, which persisted during the entire duration of drug infusion, including at 30 minutes (63 [32-93] versus 214 [183-245]; mean difference, 152 [95% CI, 108-195]; P<0·001; primary end point). Parallel findings were shown with platelet reactivity index. Accordingly, high on-treatment platelet reactivity rates were reduced with cangrelor. After discontinuation of cangrelor/placebo infusion, there were no differences in levels of platelet reactivity between groups, ruling out a drug-drug interaction when cangrelor and ticagrelor are concomitantly administered. CONCLUSIONS: In patients undergoing primary percutaneous coronary intervention, cangrelor is an effective strategy to bridge the gap in platelet inhibition associated with the use of oral P2Y12 inhibition induced by ticagrelor. Ticagrelor can be administered as a crushed formulation concomitantly with cangrelor without any apparent drug-drug interaction. The clinical implications of these pharmacodynamic findings warrant investigation in an adequately powered clinical trial. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03247738.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Franchi F, Rollini F, Rivas A, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2019. PMID: 30630341. doi:10.1161/CIRCULATIONAHA.118.038317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。